IBL News

IBL products introduced in this IBL news are applicable for research use only and cannot be used for diagnostic or medical purposes.
 
  Angiopoietin-like protein 3 (ANGPTL3) is a liver-derived secreted protein that increases blood TG and LDL-C levels by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Previous studies have suggested that elevated ANGPTL3 levels may contribute to the progression of atherosclerosis, but a direct association with plaque calcification has remained unclear.

  A research group led by Dr. Yu Kataoka of the Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center, analyzed the association between the degree of coronary plaque calcification and serum ANGPTL3 levels in 58 patients with coronary artery disease (CAD) who underwent optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), including 23 patients with acute coronary syndrome (ACS) and 35 patients with stable CAD.
  Consequently, higher ANGPTL3 levels were found to be significantly associated with a larger maximum calcification arc and a longer calcification length.
　Maximum calcification arc: r = 0.672, P < 0.001
　Calcification length: r = 0.561, P < 0.001

  This correlation was consistently observed in both the ACS group and the stable CAD group. Furthermore, in the multivariate analysis adjusted for age and sex, ANGPTL3 levels also remained independent predictors of the maximum calcification arc and calcification length.
　Maximum calcification arc: β = 0.143, P < 0.001
　Calcification length: β = 0.013, P < 0.001

  ROC analysis identified an ANGPTL3 level of ≥ 410.9 ng/mL as the optimal cutoff for predicting severe calcification. Notably, in patients with both elevated ANGPTL3 levels (≥ 410.9 ng/mL) and reduced eGFR (≤ 65.2 mL/min/1.73 m²), the prevalence of severe calcification in non-culprit lesions was significantly higher (46.2%).
  This study demonstrates that serum ANGPTL3 levels are an independent factor associated with coronary plaque calcification, suggesting that ANGPTL3 may represent a potential therapeutic target in patients with CAD. Further large-scale, multicenter studies are warranted to clarify the causal relationship. This study is a pioneering and significant contribution to understanding the link between ANGPTL3 and coronary plaque calcification.

Please refer to the following publication for more details.
Yu Kataoka et al.
Circulating Angiopoietin-Like Protein 3 Level and Plaque Calcification: An Optical Coherence Tomography Imaging Analysis CJC Open.
2025 12;7:1204-1213.

This study used the following IBL ELISA kit to measure ANGPTL3.
27750 Human ANGPTL3 (highly sensitive) Assay Kit - IBL

We offer a wide range of ELISA kits for lipid metabolism research and also provide testing services.

■ANGPTL3
Angiopoietin-like protein 3 (ANGPTL3) is a liver-derived, hormone-like protein that plays a role in lipid metabolism and angiogenesis. It is structurally similar to the angiopoietin family, which participates in angiogenesis, and possesses a coiled-coil domain and a fibrinogen-like domain, although no binding to the Tie family has been observed. ANGPTL3 is also regulated by LXR and has emerged as a novel secreted factor of interest.

We hope this information will be useful for your research.
Please feel free to contact us.
 
Sales Department
Antibody related Business Division
Immuno-Biological Laboratories Co., Ltd.
Email: do-ibl@ibl-japan.co.jp
 

---

IBL-Japan (Specific Antibody Development) 30sec video

IBL-Japan (Specific Antibody Development) 2min video

LipoSEARCH® - Lipoprotein Analyzing Systems (Patented GP-HPLC Systems) 30sec video